NO20015021L - Fremgangsmåte til å nedregulere IL-5 aktivitet - Google Patents

Fremgangsmåte til å nedregulere IL-5 aktivitet

Info

Publication number
NO20015021L
NO20015021L NO20015021A NO20015021A NO20015021L NO 20015021 L NO20015021 L NO 20015021L NO 20015021 A NO20015021 A NO 20015021A NO 20015021 A NO20015021 A NO 20015021A NO 20015021 L NO20015021 L NO 20015021L
Authority
NO
Norway
Prior art keywords
modified
present
ils
well
analogs
Prior art date
Application number
NO20015021A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015021D0 (no
Inventor
Steen Klysner
Original Assignee
Pharmexa As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa As filed Critical Pharmexa As
Publication of NO20015021D0 publication Critical patent/NO20015021D0/no
Publication of NO20015021L publication Critical patent/NO20015021L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Massaging Devices (AREA)
NO20015021A 1999-04-23 2001-10-15 Fremgangsmåte til å nedregulere IL-5 aktivitet NO20015021L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199900552 1999-04-23
US13281199P 1999-05-06 1999-05-06
PCT/DK2000/000205 WO2000065058A1 (en) 1999-04-23 2000-04-19 Method for down-regulating il5 activity

Publications (2)

Publication Number Publication Date
NO20015021D0 NO20015021D0 (no) 2001-10-15
NO20015021L true NO20015021L (no) 2001-12-21

Family

ID=26064209

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015021A NO20015021L (no) 1999-04-23 2001-10-15 Fremgangsmåte til å nedregulere IL-5 aktivitet

Country Status (19)

Country Link
US (2) US7285273B1 (cs)
EP (1) EP1173573A1 (cs)
JP (1) JP2002543098A (cs)
KR (1) KR20020084841A (cs)
CN (1) CN1355846A (cs)
AU (1) AU777952B2 (cs)
CA (1) CA2370391A1 (cs)
CZ (1) CZ20013709A3 (cs)
EA (1) EA200101125A1 (cs)
EE (1) EE200100552A (cs)
HR (1) HRP20010824A2 (cs)
HU (1) HUP0200958A3 (cs)
IL (1) IL145786A0 (cs)
MX (1) MXPA01010625A (cs)
NO (1) NO20015021L (cs)
PL (1) PL351986A1 (cs)
SK (1) SK14832001A3 (cs)
TR (1) TR200103046T2 (cs)
WO (1) WO2000065058A1 (cs)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7097837B2 (en) 2001-02-19 2006-08-29 Pharmexa A/S Synthetic vaccine agents
ATE419007T1 (de) * 2001-11-07 2009-01-15 Cytos Biotechnology Ag Antigenraster welche il-5, il-13 oder eotaxin präsentieren, zur behandlung von allergischen, eosinophilen erkrankungen
JP4533626B2 (ja) * 2001-11-07 2010-09-01 サイトス バイオテクノロジー アーゲー アレルギー性好酸球性疾患を治療するための抗原アレイ
WO2003042244A2 (en) * 2001-11-16 2003-05-22 Pharmexa A/S Immunogenic mimetics of multimer proteins with promiscuous t cell epitope inserts
EP1534323A2 (en) * 2002-08-30 2005-06-01 Glaxo Group Limited Il-14 vaccine for the treatment of asthma and atopic disorders
AU2003259358A1 (en) * 2002-08-30 2004-03-19 Claire Ashman Immunogenic composition comprising an il-13 element and t cell epitopes, and its therapeutic use
JP2007525436A (ja) * 2003-03-24 2007-09-06 マーシア・ファーマ・インコーポレイテッド 炎症症状を処置および予防するための方法および組成物
CN103091499B (zh) * 2013-01-23 2015-07-08 三峡大学 一种肿瘤标志物钙网蛋白检测试剂盒的制备及应用
JP6444321B2 (ja) * 2013-02-22 2018-12-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化主要組織適合性遺伝子複合体を発現するマウス
KR102313053B1 (ko) * 2013-03-11 2021-10-18 리제너론 파아마슈티컬스, 인크. 키메라 주요 조직적합성 복합체(ｍｈｃ) 제ｉ 부류 분자를 발현하는 유전자전이 마우스
CN112225807B (zh) * 2020-10-30 2021-09-07 上海洛启生物医药技术有限公司 抗il5纳米抗体及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096704A (en) 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
FR2677654B1 (fr) 1991-06-17 1995-11-17 Pasteur Merieux Serums Vacc Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv.
AU4377793A (en) 1992-05-20 1993-12-13 Johns Hopkins University, The Alternative receptor therapy
US5616488A (en) 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. IL-5 targeted ribozymes
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
DK0735893T3 (da) 1993-09-14 2009-03-09 Pharmexa Inc PAN DR-bindende peptider til styrkelse af immunsvaret
AU2195395A (en) 1994-03-28 1995-10-17 United Biomedical Inc. Synthetic peptide based immunogens for the treatment of allergy
AUPO005496A0 (en) 1996-05-24 1996-06-13 Bresagen Limited An interleukin-5 antagonist
CA2190494C (en) 1994-05-18 2002-05-07 Michael E. Houston Heterodimer polypeptide immunogen carrier composition and method
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
WO1997000321A1 (en) 1995-06-14 1997-01-03 Commonwealth Scientific And Industrial Research Organisation Immune response modulators and uses therefor
WO1998017799A1 (en) * 1996-10-23 1998-04-30 The Trustees Of The University Of Pennsylvania Immunotherapy and improved vaccines
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
PT1005374E (pt) 1997-01-22 2007-07-18 Mgi Pharma Biolog Inc Micropartículas para administração de ácido nucleico
AU7132098A (en) 1997-04-18 1998-11-13 Tanox Biosystems, Inc. Il-5r antagonists for treatment of inflammation, asthma and other allergic diseases
TR200100936T2 (tr) * 1998-10-05 2001-08-21 Pharmexa A/S Terapötik aşılama

Also Published As

Publication number Publication date
AU4100800A (en) 2000-11-10
US6746669B1 (en) 2004-06-08
KR20020084841A (ko) 2002-11-11
TR200103046T2 (tr) 2002-06-21
WO2000065058A1 (en) 2000-11-02
EA200101125A1 (ru) 2002-04-25
SK14832001A3 (sk) 2003-02-04
HUP0200958A2 (en) 2002-06-29
CZ20013709A3 (cs) 2002-11-13
IL145786A0 (en) 2002-07-25
NO20015021D0 (no) 2001-10-15
CA2370391A1 (en) 2000-11-02
HRP20010824A2 (en) 2002-12-31
EP1173573A1 (en) 2002-01-23
US7285273B1 (en) 2007-10-23
PL351986A1 (en) 2003-07-14
MXPA01010625A (es) 2003-09-04
JP2002543098A (ja) 2002-12-17
HUP0200958A3 (en) 2004-11-29
CN1355846A (zh) 2002-06-26
EE200100552A (et) 2002-12-16
AU777952B2 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
NO20015021L (no) Fremgangsmåte til å nedregulere IL-5 aktivitet
Koppelman et al. Purification and immunoglobulin E‐binding properties of peanut allergen Ara h 6: evidence for cross‐reactivity with Ara h 2
Kettner et al. Api m 6: a new bee venom allergen
DE69924392D1 (de) Verfahren zur hemmung der aktivität von osteoprotegerin-liganden
Gavrovic-Jankulovic et al. A novel recombinantly produced banana lectin isoform is a valuable tool for glycoproteomics and a potent modulator of the proliferation response in CD3+, CD4+, and CD8+ populations of human PBMCs
WO1998014596A3 (en) Disease associated protein tyrosine phosphatases
Petersen et al. Group 13 grass allergens: structural variability between different grass species and analysis of proteolytic stability
Grobe et al. Properties of group I allergens from grass pollen and their relation to cathepsin B, a member of the C1 family of cysteine proteinases
Hoffman Allergens in Hymenoptera venom XVI: Studies of the structures and cross-reactivities of vespid venom phospholipases
Gantulga et al. The Arabidopsis At1g45130 and At3g52840 genes encode β-galactosidases with activity toward cell wall polysaccharides
Welle et al. Properties and solubilization of the prenyltransferase of isoflavonoid phytoalexin biosynthesis in soybean
WO1998018822A3 (en) Novel human lim proteins
Wopfner et al. The alpha and beta subchain of Amb a 1, the major ragweed-pollen allergen show divergent reactivity at the IgE and T-cell level
WO1998025956A3 (en) Human GTP-binding proteins
Kohama et al. Ca2+-binding light chain of Physarum myosin confers inhibitory Ca2+-sensitivity on Actin-myosin-ATP interaction via actin
Nakayama et al. Affinity purification of nicotinic acetylcholine receptor from rat brain
AU776154B2 (en) Method for isolating and purifying grass pollen allergens
EP3430390A1 (en) Molecular origin of allergy
Hülsmann et al. Cardiac lipoprotein lipase: effects of lipopolysaccharide and tumor necrosis factor
Etzler Isolation and characterization of subunits of DB58, a lectin from the stems and leaves of Dolichos biflorus
Dhyani et al. A clinically relevant major cross‐reactive allergen from mesquite tree pollen
WO2012105541A1 (ja) 新規ヒノキ花粉アレルゲン
Müller et al. Ubiquitin and ubiquitination in cells from the marine sponge Geodia cydonium
WO1998018942A3 (en) Novel human rab proteins
WO1998036068A3 (en) Human p24 vesicle proteins

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application